The University of Queensland

Promics Pty Limited

Lindsay Charles Brown

David P Fairlie

Stephen Maxwell Taylor

Robert C Reid

Ligong Liu

Ian Alexander Shiels

Jacky Yung Suen

Michael Wellesley Whitehouse

Rink-Jan Lohman

Mei-Kwan Yau

Abishek Venkatasubramanian Iyer

Junxian Lim

The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities. 

Modulators of protease activated receptors

This invention relates to the use of an antagonist of a G protein-coupled receptor in the prevention and/or treatment of fibrosis, such as the treatment of fibrosis associated with myocardial infarction or diabetes or certain pulmonary conditions. In a preferred embodiment, the antagonist is a C5a receptor antagonist, more preferably a cyclic peptide antagonist of the C5a receptor. In particular, the invention provides a method of prevention, treatment or alleviation of a fibrotic condition, comprising the step of administering an effective amount of an antagonist of a G protein-coupled receptor to a subject in need of such treatment.

Use of C5a receptor antagonist in the treatment of fibrosis

Growing community of inventors

Sinnamon Park, Australia

Lindsay Charles Brown